Hill-Rom picks up patient positioning player Tridien Medical

Coral Springs, FL

Hill-Rom subsidiary Comfort Holdings has acquired all outstanding shares of Tridien Medical, which makes patient positioning devices and support surfaces. The deal will help Hill-Rom reduce costs and improve margins, the company said.

The deal will help Hill-Rom reduce costs by allowing it to “insource a significant supply chain function,” according to an SEC filing. Financial details were not disclosed.

While Hill-Rom is best known for its hospital beds, support surfaces and mattresses, it also markets surgical equipment, including scalpels and surgical positioning tools, as well as respiratory care devices, such as a vest-based airway clearance system.

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

Coral Springs, FL-based Tridien’s products include powered alternating pressure mattresses and nonpowered mattresses that adjust to a patient’s weight and/or position, mattresses that distribute a patient’s weight evenly to prevent pressure ulcers, and a mattress that alternates pressure to treat pressure ulcers.

In June last year, Hill-Rom announced it would acquire Welch Allyn for $2 billion. The deal saw Hill-Rom picking up patient-oriented diagnostics and monitoring devices, which allowed the company to round out its offerings and become “an even more relevant partner to acute care providers,” CEO John Greisch said at the time.

Suggested Articles

By employing heart rate signals, physical activity and sleep quality, common Fitbit trackers may be able to predict the spread of the flu.

Nanox has raised $26 million to help fuel the development and commercialization of its Star Trek-inspired digital X-ray bed.

Oncology is clearly a major medical and societal issue, but one that sees too much focus from biopharmas at the expense of other killers.